At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02575 XUANZHUBIO-B
Market Closed 03-06 16:08:17
50.000
-3.100
-5.84%
High53.750
Low48.620
Vol664.50K
Open51.800
D1 Closing53.100
Amplitude9.66%
Mkt Cap25.90B
Tradable Cap8.04B
Total Shares518.00M
T/O33.73M
T/O Rate0.41%
Tradable Shares160.70M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
XUANZHUBIO-B (02575) Publishes Monthly Return for 28 February 2026
**Xuanzhu Biopharmaceutical Joins Hang Seng Composite Index**Xuanzhu Biopharmaceutical Co., Ltd. said it will be included as a constituent stock of the Hang Seng Composite Index following Hang Seng Indexes’ quarterly review, with the change taking effect on March 9, 2026
Hong Kong Stocks Movement | Xuanzhu Bio-B (02575) Surges Over 6% in Early Trading, Innovative Drug Piroxiclib Set for National Reimbursement on Jan 1, 2026
Xuanzhu Biopharmaceutical Co Ltd is a China-based company principally engaged in biopharmaceutical business. The Company is primarily engaged in business of research and development, manufacturing and commercialization of innovative drugs, focusing on a number of therapeutic areas such as digestion, oncology and non-alcoholic steatohepatitis (NASH). The Company’s main products include KBP-3571, XZP-3287 and XZP-3621. The Company mainly conducts its businesses in the domestic market.